Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-14 |
2024-03 |
0 |
N/A |
N/A |
N/A |
2024-03-21 |
2023-12 |
0 |
N/A |
N/A |
N/A |
2023-03-23 |
2022-12 |
0 |
N/A |
N/A |
N/A |
2022-03-24 |
2021-12 |
0 |
N/A |
N/A |
N/A |
2021-03-18 |
2020-12 |
0 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-17 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-06-15 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-03-23 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-11-14 |
SVB Leerink |
Upgrade |
|
Outperform |
2022-09-15 |
Citigroup |
Upgrade |
|
Buy |
2022-08-01 |
SVB Leerink |
Upgrade |
|
Outperform |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Optiver Holding B.v. |
81.80K |
251.52K |
0.10% |
2023-06-29 |
Millennium Management Llc |
49.45K |
152.06K |
0.06% |
2023-06-29 |
Morgan Stanley |
47.05K |
144.68K |
0.06% |
2023-09-29 |
Exchange Traded Concepts LLC |
35.00K |
88.54K |
0.04% |
2023-06-29 |
Citadel Advisors Llc |
13.28K |
40.84K |
0.02% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-05-30 |
Trust for Professional Managers-ActivePassive International Equity ETF |
6.38K |
18.76K |
0.01% |